文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性抗VEGF治疗10年结局与主要风险等位基因的关联

Long-term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles.
PubMed 文献 · Br J Ophthalmol · 2021-06-02

该研究评估了新生血管性年龄相关性黄斑变性(nvAMD)接受玻璃体腔抗VEGF治疗最长10年的功能性及解剖学结局,并对CFH、HTRA1和C3基因的主要风险等位基因进行基因分型。结果显示,80眼(29%)随访≥8年,10年间平均注射73.3±28.0次,最佳矫正视力(BCVA)从基线0.55±0.53恶化至10年时1.00±0.73(p<0.0005),黄斑中心凹厚度(CST)在三次月度注射后下降并持续低于基线。视力结局与基线BCVA、视网膜内液(IRF)、随访时黄斑萎缩及黄斑变薄相关;CST下降幅度与CFH和/或C3风险等位基因数量呈负相关(Pearson r=-0.608;p=0.003)。

要点

  • nvAMD抗VEGF治疗10年视力显著恶化,基线IRF和黄斑萎缩与视力结局相关。
  • 10年间平均注射73.3±28.0次,CST在三次月度注射后下降并持续低于基线。
  • CFH和/或C3风险等位基因数量越多,长期CST下降幅度越小。

核心结论

  • nvAMD患者接受抗VEGF治疗10年后出现显著视力丧失,与基线IRF和黄斑萎缩相关。
  • 补体基因CFH和C3的主要风险等位基因与长期黄斑厚度下降减少相关。

研究设计与样本

  • 研究纳入276只合格眼(206例患者)中80只眼(29%,66例患者,32.0%)随访≥8年。
  • 采用treat-and-extend方案行玻璃体腔抗VEGF治疗,并对CFH(rs1061170)、HTRA1(rs1200638)和C3(rs2230199)基因分型。

主要发现

  • 10年间平均注射73.3±28.0次(mean±SD)。
  • BCVA(LogMAR)从基线0.55±0.53恶化至10年时1.00±0.73(p<0.0005)。
  • CST从基线415.8±162.1 µm降至三次月度注射后323±113.6 µm(p<0.0005),随访期间持续低于基线。
  • 视力结局与基线BCVA、基线IRF、随访时黄斑萎缩及黄斑变薄相关。
  • CST下降与CFH和/或C3风险等位基因数量呈负相关(Pearson r=-0.608;p=0.003)。

关键数值与推荐

  • 10年随访眼BCVA(LogMAR)从基线0.55±0.53降至1.00±0.73(p<0.0005)。
  • CST从基线415.8±162.1 µm降至三次月度注射后323±113.6 µm(p<0.0005)。
  • CST下降与CFH和/或C3风险等位基因数量的Pearson r=-0.608(p=0.003)。

临床怎么用

  • 对nvAMD长期抗VEGF治疗患者,应关注基线IRF和黄斑萎缩对视力预后的影响。
  • CFH和C3风险等位基因可能提示长期黄斑厚度下降幅度较小,可作为预后参考。

局限性

  • 仅29%的合格眼随访≥8年,可能存在选择偏倚。
  • 原文未报告HTRA1等位基因与结局的关联结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To evaluate the long-term functional and anatomical outcomes of neovascular age-related macular degeneration (nvAMD) treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) for up to 10 years, and to identify associated risk factors. METHODS: Clinical and optical coherence tomography findings were retrieved for nvAMD cases treated with intravitreal anti-VEGF compounds using a treat-and-extend protocol. In addition, the major risk alleles for AMD in the CFH (rs1061170), HTRA1 (rs1200638) and C3 (rs2230199) genes were genotyped. RESULTS: From 276 eligible eyes in 206 patients, 80 eyes (29%) in 66 patients (32.0%) had a follow-up period of ≥8 years and were included in this study. Over a 10-year period, 73.3±28.0 (mean±SD) anti-VEGF injections were administered. Best-corrected visual acuity (BCVA; LogMAR) deteriorated from 0.55±0.53 at baseline to 1.00±0.73 at 10 years (p<0.0005). Central subfield thickness (CST) decreased from 415.8±162.1 µm at baseline to 323±113.6 µm (p<0.0005) after three monthly injections and remained lower than baseline throughout the follow-up period. Visual outcome was associated with BCVA and intraretinal fluid (IRF) at baseline, macular atrophy, and macular thinning at follow-up. The decrease in CST was inversely correlated with the number of CFH and/or C3 risk alleles carried by the patient (Pearson's r: -0.608; p=0.003). CONCLUSIONS: Patients with nvAMD who received anti-VEGF therapy for 10 years developed substantial vision loss associated with the presence of IRF at baseline and macular atrophy. Major risk alleles for AMD in two complement genes were associated with a reduced long-term reduction in macular thickness.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Vofo BN, Beykin G, Levy J, et al. Long-term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles. Br J Ophthalmol. 2021. PMID: 34083208. doi:10.1136/bjophthalmol-2021-319054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。